Quick Answer
TriSalus Life Sciences, Inc. reported Research And Development Expense of $14.97 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -15.4% in Research And Development Expense from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $4.81 million | Q1 2023: $5.64 million | Q2 2023: $6.89 million | Q3 2023: $9.51 million | Q1 2024: $5.84 million | Q2 2024: $4.67 million | Q3 2024: $4.22 million | Q1 2025: $3.30 million | Q2 2025: $3.92 million | Q3 2025: $5.18 million.
- Over the full 4 years of available data (2022 to 2025), TriSalus Life Sciences, Inc.'s Research And Development Expense has declined by 29.9%.
- Historical annual values: Fiscal year 2025: $14.97 million | Fiscal year 2024: $17.69 million | Fiscal year 2023: $29.84 million | Fiscal year 2022: $21.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: